Skip to main content
Top
Published in: Clinical and Experimental Nephrology 9/2020

01-09-2020 | Kidney Transplantation | Original article

Two-year retrospective study of the effect of preemptive kidney transplantation and pretransplant mineral bone factors on calcium in post-kidney transplant recipients

Authors: Makoto Tsujita, Norihiko Goto, Kenta Futamura, Manabu Okada, Takahisa Hiramitsu, Shunji Narumi, Kazuharu Uchida, Kunio Morozumi, Yoshihiko Watarai

Published in: Clinical and Experimental Nephrology | Issue 9/2020

Login to get access

Abstract

Background

Preemptive kidney transplantation (PEKT) incidence has recently increased in Japan. The effect of PEKT and mineral bone factors before kidney transplantation (KTx) on long-term calcium (Ca) levels remains unknown.

Methods

Eighty-one consecutive patients at Nagoya Daini Red Cross Hospital were included in this study (PEKT group with 41 patients and non PEKT group with 40 patients). Ca metabolism, including intact fibroblast growth factor 23 (iFGF23), were measured before KTx and intact parathyroid hormone (iPTH), and corrected Ca (cCa) were measured before KTx and 6 months (M), 12 M, and 24 M after KTx.

Results

In PEKT group, cCa levels at 24 M were higher from the baseline level. At baseline, cCa levels had a positive correlation with iFGF23 levels (r = 0.51; p < 0.001) and a negative correlation with iPTH levels (r = 0.51; p < 0.001). The cCa difference between baseline and 24 M was 0.8 ± 0.6 mg/dL in PEKT group and 0.3 ± 0.7 mg/dL in non-PEKT group (p = 0.001). A multivariate linear regression analysis showed iFGF23 and iPTH at baseline in entire groups were useful markers on calcium levels at 24 M. However, in PEKT group, both markers were found to be not associated with Ca at 24 M, whereas in non PEKT group, iPTH was the only effective marker.

Conclusions

This study suggested that iFGF23 and iPTH may be useful markers of the calcium status after KTx. However, no correlation was noted in PEKT group.
Literature
1.
go back to reference Kawarazaki H, Shibagaki Y, Fukumoto S, et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant. 2011;26:2691–5.CrossRef Kawarazaki H, Shibagaki Y, Fukumoto S, et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant. 2011;26:2691–5.CrossRef
2.
go back to reference Evenepoel P, Naesens M, Claes K, et al. Calcium metabolism in the early post-transplantation period. Clin J Am Soc Nephrol. 2009;4:665–72.CrossRef Evenepoel P, Naesens M, Claes K, et al. Calcium metabolism in the early post-transplantation period. Clin J Am Soc Nephrol. 2009;4:665–72.CrossRef
3.
go back to reference Tsujita M, Inaguma D, Goto N, et al. Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Clin Exp Nephrol. 2015;19:319–24.CrossRef Tsujita M, Inaguma D, Goto N, et al. Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients. Clin Exp Nephrol. 2015;19:319–24.CrossRef
4.
go back to reference Komaba H, Koizumi M, Fukagawa M, et al. Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future? Kidney Int. 2010;78:953–5.CrossRef Komaba H, Koizumi M, Fukagawa M, et al. Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future? Kidney Int. 2010;78:953–5.CrossRef
5.
go back to reference Nakai K, Fujii H, Yoshikawa K, et al. Effect of cinacalcet cessation on hyperparathyroidism in kidney transplant patients after long-term dialysis therapy. Clin Exp Nephrol. 2015;19:1184–8.CrossRef Nakai K, Fujii H, Yoshikawa K, et al. Effect of cinacalcet cessation on hyperparathyroidism in kidney transplant patients after long-term dialysis therapy. Clin Exp Nephrol. 2015;19:1184–8.CrossRef
6.
go back to reference Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
7.
go back to reference Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012;7:810–9.CrossRef Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012;7:810–9.CrossRef
8.
go back to reference Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017;100:62–8.CrossRef Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone. 2017;100:62–8.CrossRef
9.
go back to reference Alagoz S, Trabulus S. Long-term evaluation of mineral metabolism after kidney trasnplantation. Transplant Proc. 2019;51:2330–3.CrossRef Alagoz S, Trabulus S. Long-term evaluation of mineral metabolism after kidney trasnplantation. Transplant Proc. 2019;51:2330–3.CrossRef
10.
go back to reference Nakamura M, Tanaka K, Marui Y, et al. Clinicopathological analysis of persistent hypercalcemia and hyperparathyroidism after kidney transplantation in long-term dialysis patients. Ther Apher Dial. 2013;17:551–6.PubMed Nakamura M, Tanaka K, Marui Y, et al. Clinicopathological analysis of persistent hypercalcemia and hyperparathyroidism after kidney transplantation in long-term dialysis patients. Ther Apher Dial. 2013;17:551–6.PubMed
Metadata
Title
Two-year retrospective study of the effect of preemptive kidney transplantation and pretransplant mineral bone factors on calcium in post-kidney transplant recipients
Authors
Makoto Tsujita
Norihiko Goto
Kenta Futamura
Manabu Okada
Takahisa Hiramitsu
Shunji Narumi
Kazuharu Uchida
Kunio Morozumi
Yoshihiko Watarai
Publication date
01-09-2020

Other articles of this Issue 9/2020

Clinical and Experimental Nephrology 9/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.